Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Value of Intestinal Ultrasound in Predicting Vedolizumab Response and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study

NCT07093294 is registered in ClinicalTrials.gov with The Third Xiangya Hospital of Central South University as lead sponsor.

NCT NCT07093294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07093294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Value of Intestinal Ultrasound in Predicting Vedolizumab Response and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study
Lead sponsor
The Third Xiangya Hospital of Central South University
Phase
Observational
Overall status
Recruiting
Start date
June 1, 2025
Completion date
September 30, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease (cd), intestinal ultrasound, predictor, vedolizumab